Nasdaq Clbs News Today

Equities research analysts expect Caladrius Biosciences, Inc. (NASDAQ:CLBS – Get Rating) to report ($0.10) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Caladrius Biosciences’ earnings. The highest EPS estimate is ($0.06) and the lowest is ($0.12). Caladrius Biosciences also reported earnings per share of ($0.10) […]

Caladrius Biosciences, Inc. (NASDAQ:CLBS – Get Rating) was the target of a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 541,400 shares, a drop of 43.1% from the April 30th total of 952,200 shares. Currently, 0.9% of the company’s shares are sold short. Based […]

Caladrius Biosciences (NASDAQ:CLBS – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Tuesday, Zacks.com reports. The firm presently has a $0.50 price objective on the biotechnology company’s stock. Zacks Investment Research‘s target price indicates a potential upside of 8.65% from the stock’s […]

Caladrius Biosciences (NASDAQ:CLBS – Get Rating) issued its earnings results on Thursday. The biotechnology company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03, MarketWatch Earnings reports. During the same period in the prior year, the company earned ($0.19) earnings per share. Shares of NASDAQ CLBS traded down […]

StockNews.com assumed coverage on shares of Caladrius Biosciences (NASDAQ:CLBS – Get Rating) in a report released on Tuesday. The brokerage issued a sell rating on the biotechnology company’s stock. Separately, HC Wainwright cut their price target on Caladrius Biosciences from $8.00 to $6.00 and set a buy rating on the stock in a research note […]

Wall Street analysts expect Caladrius Biosciences, Inc. (NASDAQ:CLBS – Get Rating) to report earnings of ($0.12) per share for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Caladrius Biosciences’ earnings, with estimates ranging from ($0.12) to ($0.11). Caladrius Biosciences reported earnings per share of ($0.19) in the same quarter last […]

StockNews.com initiated coverage on shares of Caladrius Biosciences (NASDAQ:CLBS – Get Rating) in a research note issued to investors on Sunday. The firm set a “sell” rating on the biotechnology company’s stock. Separately, HC Wainwright cut their price objective on Caladrius Biosciences from $8.00 to $6.00 and set a “buy” rating for the company in […]

Analysts expect that Caladrius Biosciences, Inc. (NASDAQ:CLBS – Get Rating) will announce ($0.15) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Caladrius Biosciences’ earnings. The lowest EPS estimate is ($0.16) and the highest is ($0.13). Caladrius Biosciences posted earnings per share of ($0.28) […]